Recent Updates
Recently added Catalysts

PF-05280602

Phase 1

Hemophilia A | Monoclonal antibody | Hematology |Gyre Therapeutics, Inc.|Last Updated: May 11, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment29
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01439971Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With HemophiliaPHASE1 COMPLETED 29Dec 1, 2011Oct 1, 2015May 11, 2017 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
PF-05280602BIOLOGICAL0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
Unlock Study Design Details